Sitagliptin phosphate | CAS#654671-78-0 | DPP4 inhibitor

Sitagliptin phosphate
featured

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 333071

CAS#: 654671-78-0 (phosphate)

Description: Sitagliptin, also known as MK-0431, is a potent inhibitor of DPP4 with an IC50 of 19 nM in Caco-2 cell extracts. Sitagliptin is believed to exert its actions in patients with type 2 diabetes mellitus by slowing the inactivation of incretin hormones. By increasing and prolonging active incretin levels, sitagliptin increases insulin release and decreases glucagon levels in the circulation in a glucose-dependent manner. Sitagliptin demonstrates selectivity for DPP-4 and does not inhibit DPP-8 or DPP-9 activity in vitro at concentrations approximating those from therapeutic doses.

Chemical Structure

Sitagliptin phosphate

CAS# 654671-78-0 (phosphate)

Instruction

Theoretical Analysis

MedKoo Cat#: 333071
Name: Sitagliptin phosphate
CAS#: 654671-78-0 (phosphate)
Chemical Formula: C16H18F6N5O5P
Exact Mass: 0.00
Molecular Weight: 505.314
Elemental Analysis: C, 38.03; H, 3.59; F, 22.56; N, 13.86; O, 15.83; P, 6.13

Price and Availability

Size	Price	Availability
500mg	USD 350	2 Weeks
1g	USD 550	2 Weeks
2g	USD 950	2 Weeks
5g	USD 1950	2 Weeks
10g	USD 2950	2 Weeks
Bulk inquiry Welcome, Customer: Please do not inquire quote if your intended use is for a patient since our products are for research use and for chemical synthesis use, not for human use . For in-stock products, we listed price in the web page. You may inquire prices for which sizes were not listed. If no price is listed, this means the product is not in stock at the moment, which may be available via custom synthesis. For cost-effective reason, minimum order of 1g is requested (typically very expensive). The lead time is usually 2-4 months. Quote of less than 1g will not be provided. MedKoo may not offer quote for below reasons: (1) current available synthetic method appears to be extremely expensive which is obviously not affordable to most customers; (2) Key raw material to make the product is temporally not available; (3) DEA controlled substances; (4) the product is under patent protection in customer’s country.

Synonym: Sitagliptin phosphate; Sitagliptin; LEZ 763; LEZ-763; LEZ763; MK0431; MK 0431; MK-0431;

IUPAC/Chemical Name: (R)-3-amino-1-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)-4-(2,4,5-trifluorophenyl)butan-1-one Phosphate

InChi Key: IQFYVLUXQXSJJN-SBSPUUFOSA-N

InChi Code: InChI=1S/C16H15F6N5O.H3O4P/c17-10-6-12(19)11(18)4-8(10)3-9(23)5-14(28)26-1-2-27-13(7-26)24-25-15(27)16(20,21)22;1-5(2,3)4/h4,6,9H,1-3,5,7,23H2;(H3,1,2,3,4)/t9-;/m1./s1

SMILES Code: O=C(N1CC2=NN=C(C(F)(F)F)N2CC1)C[C@H](N)CC3=CC(F)=C(F)C=C3F.O=P(O)(O)O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Instruction:

View handling instruction

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 505.31 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

1: Zeng DK, Xiao Q, Li FQ, Tang YZ, Jia CL, Tang XW. Cardiovascular risk of sitagliptin in treating patients with type 2 diabetes mellitus. Biosci Rep. 2019 Jul 15;39(7):BSR20190980. doi: 10.1042/BSR20190980. PMID: 31262972; PMCID: PMC6629947.

2: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006–. Sitagliptin. 2019 Feb 7. PMID: 30000709.

3: Wiciński M, Wódkiewicz E, Słupski M, Walczak M, Socha M, Malinowski B, Pawlak-Osińska K. Neuroprotective Activity of Sitagliptin via Reduction of Neuroinflammation beyond the Incretin Effect: Focus on Alzheimer's Disease. Biomed Res Int. 2018 Aug 16;2018:6091014. doi: 10.1155/2018/6091014. PMID: 30186862; PMCID: PMC6116461.

4: Zhou Y, Guo Z, Yan W, Wang W. Cardiovascular effects of sitagliptin - An anti-diabetes medicine. Clin Exp Pharmacol Physiol. 2018 Jul;45(7):628-635. doi: 10.1111/1440-1681.12953. Epub 2018 May 20. PMID: 29679391.

5: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. Sitagliptin. 2018 Jan 3. PMID: 31643413.

6: Mega C, Teixeira-de-Lemos E, Fernandes R, Reis F. Renoprotective Effects of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin: A Review in Type 2 Diabetes. J Diabetes Res. 2017;2017:5164292. doi: 10.1155/2017/5164292. Epub 2017 Aug 27. PMID: 29098166; PMCID: PMC5643039.

7: Sharma M, Beckley N, Nazareth I, Petersen I. Effectiveness of sitagliptin compared to sulfonylureas for type 2 diabetes mellitus inadequately controlled on metformin: a systematic review and meta-analysis. BMJ Open. 2017 Oct 30;7(10):e017260. doi: 10.1136/bmjopen-2017-017260. PMID: 29084794; PMCID: PMC5665259.

8: Keshavarz K, Lotfi F, Sanati E, Salesi M, Hashemi-Meshkini A, Jafari M, Mojahedian MM, Najafi B, Nikfar S. Linagliptin versus sitagliptin in patients with type 2 diabetes mellitus: a network meta-analysis of randomized clinical trials. Daru. 2017 Oct 25;25(1):23. doi: 10.1186/s40199-017-0189-6. PMID: 29070077; PMCID: PMC5655990.

9: Li M, Yang Y, Jiang D, Ying M, Wang Y, Zhao R. Efficacy and safety of liraglutide versus sitagliptin both in combination with metformin in patients with type 2 diabetes: A systematic review and meta-analysis. Medicine (Baltimore). 2017 Sep;96(39):e8161. doi: 10.1097/MD.0000000000008161. PMID: 28953663; PMCID: PMC5626306.

10: Scott LJ. Sitagliptin: A Review in Type 2 Diabetes. Drugs. 2017 Feb;77(2):209-224. doi: 10.1007/s40265-016-0686-9. PMID: 28078647.

11: Hayes J, Anderson R, Stephens JW. Sitagliptin/metformin fixed-dose combination in type 2 diabetes mellitus: an evidence-based review of its place in therapy. Drug Des Devel Ther. 2016 Jul 19;10:2263-70. doi: 10.2147/DDDT.S93076. PMID: 27486305; PMCID: PMC4958358.

12: Alshali KZ, Karawagh AM. A review of glycemic efficacy of liraglutide once daily in achieving glycated hemoglobin targets compared with exenatide twice daily, or sitagliptin once daily in the treatment of type 2 diabetes. Saudi Med J. 2016 Aug;37(8):834-42. doi: 10.15537/smj.2016.8.15800. PMID: 27464858; PMCID: PMC5018698.

13: Suresh PS, Srinivas NR, Mullangi R. A concise review of the bioanalytical methods for the quantitation of sitagliptin, an important dipeptidyl peptidase-4 (DPP4) inhibitor, utilized for the characterization of the drug. Biomed Chromatogr. 2016 May;30(5):749-71. doi: 10.1002/bmc.3705. Epub 2016 Mar 14. PMID: 26873580.

14: Fan M, Li Y, Zhang S. Effects of Sitagliptin on Lipid Profiles in Patients With Type 2 Diabetes Mellitus: A Meta-analysis of Randomized Clinical Trials. Medicine (Baltimore). 2016 Jan;95(2):e2386. doi: 10.1097/MD.0000000000002386. PMID: 26765417; PMCID: PMC4718243.

15: Lee M, Rhee MK. Sitagliptin for Type 2 diabetes: a 2015 update. Expert Rev Cardiovasc Ther. 2015 Jun;13(6):597-610. doi: 10.1586/14779072.2015.1046840. PMID: 26000559.

16: Cornell S. Review of empagliflozin monotherapy for previously untreated patients with type 2 diabetes mellitus: Comparison with sitagliptin. Postgrad Med. 2015 Apr;127(3):277-81. doi: 10.1080/00325481.2015.1018798. Epub 2015 Feb 27. PMID: 25724655.

17: Ramadan WH, Kabbara WK. Sitagliptin/Simvastatin: a first combination tablet to treat type 2 diabetes and hypercholesterolemia--a review of its characteristics. Vasc Health Risk Manag. 2015 Feb 11;11:125-32. doi: 10.2147/VHRM.S79198. PMID: 25709467; PMCID: PMC4334171.

18: Du Q, Wang YJ, Yang S, Han P. Clinical utility and patient considerations in the use of the sitagliptin-metformin combination in Chinese patients. Patient Prefer Adherence. 2015 Feb 9;9:281-7. doi: 10.2147/PPA.S64691. PMID: 25709414; PMCID: PMC4332288.

19: Chang MW, Chen CH, Chen YC, Wu YC, Zhen YY, Leu S, Tsai TH, Ko SF, Sung PH, Yang CC, Chiang HJ, Chang HW, Chen YT, Yip HK. Sitagliptin protects rat kidneys from acute ischemia-reperfusion injury via upregulation of GLP-1 and GLP-1 receptors. Acta Pharmacol Sin. 2015 Jan;36(1):119-30. doi: 10.1038/aps.2014.98. Epub 2014 Dec 15. PMID: 25500876; PMCID: PMC4571325.

20: Wang T, Gou Z, Wang F, Ma M, Zhai SD. Comparison of GLP-1 analogues versus sitagliptin in the management of type 2 diabetes: systematic review and meta- analysis of head-to-head studies. PLoS One. 2014 Aug 4;9(8):e103798. doi: 10.1371/journal.pone.0103798. PMID: 25089625; PMCID: PMC4121242.

Your view history

Sitagliptin phosphate featured